US Patent 7,803,840: Scope, Claim Strength, and US Landscape for Dimethyl Fumarate (Autoimmune Indications Excluding Psoriatic Arthritis)
US Patent 7,803,840 claims a method of treating specific autoimmune diseases with a pharmaceutical preparation whose only active ingredient is dimethyl fumarate and whose formulation includes excipients/carriers. The claims draw a hard line around autoimmune polyarthritis and multiple sclerosis, while expressly excluding psoriatic arthritis. The strongest enforceable subject matter is the claimed treatment method + the “only active ingredient is dimethyl fumarate” limitation, paired with specific dose ranges and oral/solid/enteric-coated microtablet constructs.
This is a classic “use” plus “composition-limitation via active-ingredient exclusivity” structure. The exclusivity of “only active ingredient” is typically the main lever for infringement analysis because it limits easy design-around through addition of another active compound.
What does US 7,803,840 claim, at the method level?
Claim 1 is the independent claim and defines the core infringement boundary
Claim 1 recites a method of treating:
- Autoimmune disease selected from:
- autoimmune polyarthritis
- multiple sclerosis
- But not treating psoriatic arthritis
- By administering to a patient in need:
- an effective amount of a pharmaceutical preparation
- where the pharmaceutical preparation includes at least one excipient and/or carrier
- and dimethyl fumarate
- With the critical limitation:
- “wherein the only active ingredient for the treatment of the at least one autoimmune disease present in said pharmaceutical preparation is the dimethyl fumarate.”
Practical scope read-through
- Infringement is directed to the treatment act of a covered patient population for covered diseases.
- It is not directed to manufacturing per se (even though many dependent claims tie to dosage form).
- It is directed to a formulation-based treatment method with active-ingredient exclusivity.
What dependent claim layers tighten dose and dosage-form parameters?
Claims 2 to 9 define dimethyl fumarate content thresholds; claims 3, 10-21 define form and specific microtablet/enteric features.
Dimethyl fumarate dose content (mg per pharmaceutical preparation)
- Claim 2: dimethyl fumarate in 10 to 300 mg
- Claim 4: at least 50 mg
- Claim 5: at least 110 mg
- Claim 6: at least 120 mg
- Claims 7-9: exact content variants:
- Claim 7: 50 mg
- Claim 8: 110 mg
- Claim 9: 120 mg
Scope implication
- The patent is structured to capture multiple dosing strengths and packaging configurations that map to fixed-dose regimens.
- The “at least” claims (4-6, 5-6) broaden coverage beyond a single marketed strength.
Packaging and oral/solid formulation
- Claim 3: one or more capsules
- Claim 10: oral administration
- Claim 11: solid dosage form
- Claims 12-15: microtablets, in capsules, with per-capsule dimethyl fumarate thresholds:
- Claim 13: at least 50 mg in each capsule
- Claim 14: at least 110 mg in each capsule
- Claim 15: at least 120 mg in each capsule
Microtablet geometry and enteric coating
- Claim 16: microtablets are enteric-coated
- Claim 17: mean diameter 0.3 mm to 2.0 mm, exclusive of any coating
- Claim 18: mean diameter 2.0 mm, exclusive of any coating
Scope implication
- These geometry and coating limitations narrow coverage to a specific type of enteric-coated microtablet system (not just “oral dimethyl fumarate” in any form).
Carrier/excipient broad catch claims
- Claim 19: at least one carrier
- Claim 20: at least one excipient
- Claim 21: at least one excipient and at least one carrier
Scope implication
- These are weak/low-resolution limitations because most pharmaceutical oral solids contain excipients and carriers.
- They likely serve as fallback coverage and claim completeness rather than meaningful differentiation.
What is the actionable scope boundary from Claim 1’s disease and active-ingredient limitations?
Disease selection and exclusions
Claim 1 specifies:
- Covered: autoimmune polyarthritis and multiple sclerosis
- Excluded: psoriatic arthritis
Risk for enforcement
- If a product is labeled or prescribed for psoriatic arthritis, the claim language creates a direct carve-out: the method should be “not treating psoriatic arthritis.”
- Enforcement in practice usually turns on indication-to-patient mapping: what disease is actually being treated by the method.
“Only active ingredient” limitation
Claim 1 requires:
- dimethyl fumarate is the only active ingredient for treatment of the autoimmune disease in the pharmaceutical preparation.
Design-around vectors that the claim resists
- Co-therapy with another active compound as part of the same formulation: would likely violate the “only active ingredient” constraint if the other compound is “for the treatment” of the same disease.
- Fixed-dose combination tablets/capsules containing another active agent intended to treat the autoimmune disease: likely outside the claim.
Design-around vectors that can still be available
- Separate co-administration where the second active ingredient is not part of the “pharmaceutical preparation” (Claim 1 focuses on the pharmaceutical preparation being administered).
- If a competitor frames the method as treatment using dimethyl fumarate alone but the patient simultaneously receives another therapy, infringement may still hinge on what constitutes the “pharmaceutical preparation” and whether it has the “only active ingredient” limitation met.
How strong is the enforceability of the dependent claim “formulation architecture”?
Dependent claims (3, 10-18) provide narrower claim paths that are valuable in settlements because they allow infringement arguments against specific commercial dosage forms.
Strongest formulation constraints
- Enteric-coated microtablets (Claim 16)
- Microtablet mean diameter (Claims 17-18)
- Capsule delivery (Claim 3, 13-15)
- Defined dimethyl fumarate content per capsule (Claims 13-15)
These are harder to design around than “capsule” or “oral,” because they require matching:
- enteric coating performance/structure and
- microtablet size distributions (mean diameter ranges)
Weaker or general constraints
- Carrier/excipient clauses (Claims 19-21)
- Solid dosage form and oral (Claims 10-11)
These are typically ubiquitous and do not differentiate.
What is the practical infringement map for a competitor launching a dimethyl fumarate oral product in the US?
Infringement probability ladder (from Claim 1 outward)
- Highest likelihood if the competitor sells:
- dimethyl fumarate-only capsules (no added active ingredients)
- for multiple sclerosis or autoimmune polyarthritis
- and avoids psoriatic arthritis as the method being practiced
- Medium likelihood if the competitor’s product differs only in dose strength that still falls within Claim 2’s 10 to 300 mg and does not violate “only active ingredient.”
- Lower likelihood if the product is not an enteric-coated microtablet system or does not hit microtablet dimensions (Claims 16-18). The formulation-dependent claims narrow, but Claim 1 can still catch if only dimethyl fumarate is present.
Key diagnostic question for infringement analysis
Whether the competing “pharmaceutical preparation” includes only dimethyl fumarate as the active ingredient for treating the claimed disease.
What does the US patent landscape likely look like around dimethyl fumarate for MS and related autoimmune disease methods?
Even without building a claim-by-claim dossier for every US family member, the landscape for dimethyl fumarate in the US is dominated by:
- method-of-treatment patents for multiple sclerosis
- formulation patents tied to capsule/enteric-coated microtablet technology
- dosing regimen and strength coverage
US 7,803,840’s novelty emphasis (based on its claim set) is the combination of:
- autoimmune polyarthritis + multiple sclerosis
- explicit exclusion of psoriatic arthritis
- active-ingredient exclusivity to dimethyl fumarate
- enteric-coated microtablet sizing constraints
Where this patent likely sits relative to typical competitors
- If a competitor’s product is a standard dimethyl fumarate enteric formulation used for MS, it is more likely to fall under Claim 1 and potentially Claims 10-16 depending on formulation specifics.
- If a competitor uses a different release platform (non-enteric or macroform), it may avoid the microtablet claims (Claims 16-18) but may still face exposure under Claim 1 if the formulation contains only dimethyl fumarate and is used for MS/autoimmune polyarthritis.
What are the main claim-exposure areas for investors and licensing teams?
Exposure area 1: Indication practice and labeling
Because Claim 1 includes “but not treating psoriatic arthritis,” enforcement risk depends on:
- the indication actually practiced
- the “patient in need” disease
- whether the method is used for psoriatic arthritis populations
For licensing strategies, this matters because parties can negotiate carve-outs by indication, even when the active ingredient is identical.
Exposure area 2: “Only active ingredient” constraint
For formulation development and partnership deals:
- avoid adding another active ingredient “for the treatment” of the same autoimmune disease in the same pharmaceutical preparation.
- keep the active ingredient set clean in the capsule/tablet being marketed.
Exposure area 3: Microtablet enteric system alignment
If a product is built around a specific enteric microtablet technology:
- enteric coating presence and microtablet size distribution become critical.
- Claims 17-18 add a quantitative hook (mean diameter).
Claim chart summary (high-level)
| Claim |
Core limitation(s) |
Narrowing strength |
| 1 |
Treat autoimmune polyarthritis or multiple sclerosis; exclude psoriatic arthritis; administer prep where only active ingredient for treatment is dimethyl fumarate |
Foundation; high impact due to indication + “only active ingredient” |
| 2 |
Dimethyl fumarate amount 10 to 300 mg |
Medium; depends on marketed strengths |
| 3 |
Provided in one or more capsules |
Medium |
| 4-6 |
At least 50/110/120 mg |
Medium; depends on dose per unit |
| 7-9 |
Exact 50/110/120 mg |
Medium; depends on exact dose design |
| 10 |
Oral administration |
Low-Medium; common |
| 11 |
Solid dosage form |
Low-Medium; common |
| 12-15 |
Microtablets in capsules; at least 50/110/120 mg per capsule |
Medium-High if competitor uses microtablets |
| 16 |
Enteric-coated microtablets |
High; architecture-specific |
| 17-18 |
Microtablet mean diameter ranges (0.3 to <2.0 mm; or 2.0 mm) excluding coating |
High; measurable spec |
| 19-21 |
Contains excipient and/or carrier |
Low; ubiquitous |
What would “good” freedom-to-operate look like in US terms for this patent?
A freedom-to-operate posture that reduces this patent’s relevance usually aligns with one or more of these:
- the “method” is not practiced for autoimmune polyarthritis or multiple sclerosis (and instead focuses on other indications), or
- the method is used for psoriatic arthritis only (but Claim 1 is drafted to “not treating psoriatic arthritis”), or
- the pharmaceutical preparation includes another active ingredient intended for treatment (breaking the “only active ingredient is dimethyl fumarate” limitation), or
- the formulation does not use the enteric-coated microtablet size architecture targeted by Claims 16-18 (though Claim 1 can still apply).
Key Takeaways
- US 7,803,840 is a method-of-treatment patent with a strong formulation hook: the only active ingredient for treatment is dimethyl fumarate.
- The patent targets autoimmune polyarthritis and multiple sclerosis, with an explicit carve-out: “but not treating psoriatic arthritis.”
- Dose/content claims (10-300 mg and fixed/threshold mg levels) create multiple infringement entry points tied to marketed strengths.
- The formulation-dependent claims (capsules, enteric-coated microtablets, and microtablet mean diameter specs) provide high-resolution narrowing that can drive licensing and settlement leverage against specific dosage forms.
- For business decisions, the key infringement axes are:
1) indication-to-patient mapping (MS/autoimmune polyarthritis vs psoriatic arthritis),
2) active-ingredient exclusivity (dimethyl fumarate only in the pharmaceutical preparation),
3) microtablet enteric system and geometry.
FAQs
1) Is US 7,803,840 a composition patent or a method patent?
It is a method of treating claim set, with composition limitations embedded through the pharmaceutical preparation administered and its active-ingredient constraint.
2) What is the single most important limitation for infringement analysis?
The limitation that dimethyl fumarate is the only active ingredient for the treatment of the claimed autoimmune disease present in the pharmaceutical preparation.
3) Does the patent cover psoriatic arthritis?
The independent claim expressly frames treatment as “but not treating psoriatic arthritis.” The claim language excludes psoriatic arthritis from the method scope.
4) What formulation details appear in the dependent claims?
Capsule delivery; oral solid dosage forms; microtablets; enteric-coated microtablets; and mean diameter limitations excluding coating (0.3 mm to 2.0 mm, or 2.0 mm).
5) How do the mg-per-unit dependent claims matter in practice?
They let enforcement track specific dosing strengths (including “at least” thresholds and exact mg amounts) and can capture competitors whose capsule/tablet strength matches those numeric ranges.
References
[1] United States Patent and Trademark Office. US Patent 7,803,840.
